Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy

Authors

Afsoon D. Roberts, George Washington University Medical Center
Angelike P. Liappis, George Washington University Medical Center
Chris Chinn, George Washington University Medical Center
David M. Parenti, George Washington University Medical Center
Richard A. Muesing, George Washington University Medical Center
Suzanne Z. Schuck, George Washington University Medical Center
Judy Hsia, George Washington University Medical Center
Gary L. Simon, George Washington University Medical Center

Document Type

Journal Article

Publication Date

9-6-2002

Journal

AIDS

Volume

16

Issue

13

DOI

10.1097/00002030-200209060-00018

Abstract

Plasma lipid and lipoprotein levels were measured at baseline and after 8 weeks of highly active antiretroviral therapy among patients receiving delavirdine with or without a protease inhibitor (PI). In patients receiving nucleoside reverse transcriptase inhibitors (NRTI) plus delavirdine, there was a statistically significant increase in cholesterol and HDL levels, whereas those receiving NRTI plus a PI had no significant change in their HDL levels. When delavirdine was combined with a PI, there was a more dramatic increase in both cholesterol and HDL concentrations.

APA Citation

Roberts, A., Liappis, A., Chinn, C., Parenti, D., Muesing, R., Schuck, S., Hsia, J., & Simon, G. (2002). Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy. AIDS, 16 (13). http://dx.doi.org/10.1097/00002030-200209060-00018